Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Weleader Biomedical Co's revenue for the
three
months ended in Jun. 2026 was NT$339 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was NT$1,209 Mil.
Weleader Biomedical Co's Revenue per Share for the
three
months ended in Jun. 2026 was NT$6.60.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was NT$24.98.
Warning Sign:
Weleader Biomedical Co Ltd revenue per share has been in decline over the past 3 years.
During the past 6 years, Weleader Biomedical Co's highest 3-Year average Revenue per Share Growth Rate was 11.70% per year. The lowest was -7.40% per year. And the median was -6.50% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Weleader Biomedical Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Weleader Biomedical Co Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Weleader Biomedical Co's Revenue distribution charts can be found below:
* The bar in red indicates where Weleader Biomedical Co's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,209 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Weleader Biomedical Co (ROCO:7713) has a Revenue of NT$1,209 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Weleader Biomedical Co and its competitors.
Is Weleader Biomedical Co's Revenue too high?
Weleader Biomedical Co's current Revenue is NT$1,209 Mil. Overall, Weleader Biomedical Co has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's Revenue compare to ABT and SYK?
Weleader Biomedical Co's Revenue of NT$1,209 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Weleader Biomedical Co and its competitors. Weleader Biomedical Co's current Revenue is NT$1,209 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Weleader Biomedical Co (ROCO:7713) is currently considered Fairly Valued. The stock's GF Value™ is NT$74.53, compared to a current price of NT$72.90 — trading 2.2% below its estimated fair value. The current Revenue is NT$1,209 Mil. Weleader Biomedical Co's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current Revenue is NT$1,209 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Weleader Biomedical Co (ROCO:7713) Overvalued in 2026?
Based on GuruFocus' analysis, Weleader Biomedical Co stock appears to be undervalued.
The current stock price of NT$72.90 is trading 2.2% below its estimated GF Value™ of NT$74.53.
GuruFocus considers Weleader Biomedical Co to be Fairly Valued.
Key valuation signals for ROCO:7713:
Revenue: NT$1,209 Mil
GF Value™: NT$74.53 vs. price of NT$72.90 (2.2% below fair value)
No single metric tells the full story. See the ROCO:7713 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
66GF Score
Get the complete analysis for ROCO:7713
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7713 has been successfully added to your 
